Akebia Therapeutics (AKBA) EBITDA (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of EBITDA data on file, last reported at -$9.1 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$9.1 million, down 248.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$20.5 million (up 54.73% YoY), and the FY2025 annual result was -$5.3 million, up 92.3% from the prior year.
• EBITDA grew to -$9.1 million in Q1 2026 per AKBA's latest filing, from -$12.2 million in the prior quarter.
• Over five years, EBITDA peaked at $29.4 million in Q2 2022 and troughed at -$63.5 million in Q1 2022.
• A 5-year average of -$13.5 million and a median of -$11.2 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2024: EBITDA soared 135.46% in 2022, then tumbled 3814.01% in 2024.
• A 5-year view of EBITDA shows it stood at -$6.1 million in 2022, then jumped by 110.11% to $614000.0 in 2023, then plunged by 3814.01% to -$22.8 million in 2024, then soared by 46.31% to -$12.2 million in 2025, then climbed by 26.05% to -$9.1 million in 2026.
• Business Quant data shows AKBA's EBITDA at -$9.1 million in Q1 2026, -$12.2 million in Q4 2025, and $540000.0 in Q3 2025.